Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy
- 10 September 2009
- journal article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 44 (12) , 1185-1189
Abstract
The guideline on the management of anticoagulants and antiplatelet agents for endoscopic procedures was established by the Japan Gastroenterological Endoscopy Society in 2005. However, the degree to which this guideline has reached prescribing doctors in other fields has not, so far, been evaluated. Medical records of all patients who underwent scheduled endoscopy from January 2008 to December 2008 in the Department of Gastroenterology at the University of Tokyo were investigated retrospectively. Among 8921 patients underwent scheduled endoscopy, 1383 patients (15.5%) were receiving anticoagulants or antiplatelet agents. 324 patients (23.4%) were receiving warfarin as an anticoagulant. The most common antiplatelet agent was aspirin in 884 patients (63.9%), followed by ticlopidine in 150 patients (10.8%). Most patients taking warfarin alone (51.6%) or a combination of aspirin and ticlopidine (68.4%) underwent endoscopy without cessation. In contrast, most patients taking aspirin alone (46.0%) or ticlopidine alone (56.3%) underwent endoscopy after a cessation period of 6–7 days, indicating the low permeation of the cessation policy recommended in the guideline. Among 556 patients underwent endoscopy without a cessation period, 41 patients (7.4%) underwent invasive procedures including endoscopic mucosal resection. No bleeding complications were observed in patients who underwent invasive procedures without a cessation period. We revealed the low permeation of the guideline to prescribing doctors. Cessation before endoscopy to avoid bleeding complications can be dispensable.Keywords
This publication has 16 references indexed in Scilit:
- Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trialAmerican Heart Journal, 2009
- Multi‐center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in JapanJournal of Gastroenterology and Hepatology, 2009
- Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the WestGastrointestinal Endoscopy, 2008
- Antiplatelet Cilostazol Is Beneficial in Diabetic and/or Hypertensive Ischemic Stroke PatientsCerebrovascular Diseases, 2008
- Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control studyBMJ, 2006
- Guidelines of the French Society for Digestive Endoscopy (SFED)Endoscopy, 2006
- Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapyAlimentary Pharmacology & Therapeutics, 2006
- Study for determination of the optimal cessation period of therapy with anti-platelet agents prior to invasive endoscopic proceduresJournal of Gastroenterology, 2005
- European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokeJournal of the Neurological Sciences, 1996
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994